The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.

The rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to selectively control exposure to P. falciparum during different periods in infanc...

Full description

Bibliographic Details
Main Authors: Caterina Guinovart, Carlota Dobaño, Quique Bassat, Augusto Nhabomba, Llorenç Quintó, Maria Nélia Manaca, Ruth Aguilar, Mauricio H Rodríguez, Arnoldo Barbosa, John J Aponte, Alfredo G Mayor, Montse Renom, Cinta Moraleda, David J Roberts, Evelin Schwarzer, Peter N Le Souëf, Louis Schofield, Chetan E Chitnis, Denise L Doolan, Pedro L Alonso
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3296698?pdf=render
id doaj-c8b9e3d0df0d4998a97eafe06f467fde
record_format Article
spelling doaj-c8b9e3d0df0d4998a97eafe06f467fde2020-11-24T21:30:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0173e3236210.1371/journal.pone.0032362The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.Caterina GuinovartCarlota DobañoQuique BassatAugusto NhabombaLlorenç QuintóMaria Nélia ManacaRuth AguilarMauricio H RodríguezArnoldo BarbosaJohn J AponteAlfredo G MayorMontse RenomCinta MoraledaDavid J RobertsEvelin SchwarzerPeter N Le SouëfLouis SchofieldChetan E ChitnisDenise L DoolanPedro L AlonsoThe rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to selectively control exposure to P. falciparum during different periods in infancy and explore the effect of age in the build-up of NAI, measured as risk of clinical malaria.A three-arm double-blind randomized placebo-controlled trial was conducted in 349 infants born to Mozambican HIV-negative women. The late exposure group (LEG) received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months; the early exposure group (EEG) received placebo from 2.5-4.5 months and SP+AS from 5.5-9.5 months; and the control group (CG) received placebo from 2.5-9.5 months. Active and passive case detection (PCD) were conducted from birth to 10.5 and 24 months respectively. The primary endpoint was time to first or only episode of malaria in the second year detected by PCD. The incidence of malaria during the second year was of 0.50, 0.51 and 0.35 episodes/PYAR in the LEG, EEG and CG respectively (p = 0.379 for the adjusted comparison of the 3 groups). The hazard ratio of the adjusted comparison between the LEG and the CG was 1.38 (0.83-2.28, p = 0.642) and that between the EEG and the CG was 1.35 (0.81-2.24, p = 0.743).After considerably interfering with exposure during the first year of life, there was a trend towards a higher risk of malaria in the second year in children who had received chemoprophylaxis, but there was no significant rebound. No evidence was found that the age of first exposure to malaria affects the rate of acquisition of NAI. Thus, the timing of administration of antimalarial interventions like malaria vaccines during infancy does not appear to be a critical determinant.ClinicalTrials.gov NCT00231452.http://europepmc.org/articles/PMC3296698?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Caterina Guinovart
Carlota Dobaño
Quique Bassat
Augusto Nhabomba
Llorenç Quintó
Maria Nélia Manaca
Ruth Aguilar
Mauricio H Rodríguez
Arnoldo Barbosa
John J Aponte
Alfredo G Mayor
Montse Renom
Cinta Moraleda
David J Roberts
Evelin Schwarzer
Peter N Le Souëf
Louis Schofield
Chetan E Chitnis
Denise L Doolan
Pedro L Alonso
spellingShingle Caterina Guinovart
Carlota Dobaño
Quique Bassat
Augusto Nhabomba
Llorenç Quintó
Maria Nélia Manaca
Ruth Aguilar
Mauricio H Rodríguez
Arnoldo Barbosa
John J Aponte
Alfredo G Mayor
Montse Renom
Cinta Moraleda
David J Roberts
Evelin Schwarzer
Peter N Le Souëf
Louis Schofield
Chetan E Chitnis
Denise L Doolan
Pedro L Alonso
The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
PLoS ONE
author_facet Caterina Guinovart
Carlota Dobaño
Quique Bassat
Augusto Nhabomba
Llorenç Quintó
Maria Nélia Manaca
Ruth Aguilar
Mauricio H Rodríguez
Arnoldo Barbosa
John J Aponte
Alfredo G Mayor
Montse Renom
Cinta Moraleda
David J Roberts
Evelin Schwarzer
Peter N Le Souëf
Louis Schofield
Chetan E Chitnis
Denise L Doolan
Pedro L Alonso
author_sort Caterina Guinovart
title The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
title_short The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
title_full The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
title_fullStr The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
title_full_unstemmed The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
title_sort role of age and exposure to plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description The rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to selectively control exposure to P. falciparum during different periods in infancy and explore the effect of age in the build-up of NAI, measured as risk of clinical malaria.A three-arm double-blind randomized placebo-controlled trial was conducted in 349 infants born to Mozambican HIV-negative women. The late exposure group (LEG) received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months; the early exposure group (EEG) received placebo from 2.5-4.5 months and SP+AS from 5.5-9.5 months; and the control group (CG) received placebo from 2.5-9.5 months. Active and passive case detection (PCD) were conducted from birth to 10.5 and 24 months respectively. The primary endpoint was time to first or only episode of malaria in the second year detected by PCD. The incidence of malaria during the second year was of 0.50, 0.51 and 0.35 episodes/PYAR in the LEG, EEG and CG respectively (p = 0.379 for the adjusted comparison of the 3 groups). The hazard ratio of the adjusted comparison between the LEG and the CG was 1.38 (0.83-2.28, p = 0.642) and that between the EEG and the CG was 1.35 (0.81-2.24, p = 0.743).After considerably interfering with exposure during the first year of life, there was a trend towards a higher risk of malaria in the second year in children who had received chemoprophylaxis, but there was no significant rebound. No evidence was found that the age of first exposure to malaria affects the rate of acquisition of NAI. Thus, the timing of administration of antimalarial interventions like malaria vaccines during infancy does not appear to be a critical determinant.ClinicalTrials.gov NCT00231452.
url http://europepmc.org/articles/PMC3296698?pdf=render
work_keys_str_mv AT caterinaguinovart theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT carlotadobano theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT quiquebassat theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT augustonhabomba theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT llorencquinto theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT marianeliamanaca theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT ruthaguilar theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT mauriciohrodriguez theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT arnoldobarbosa theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT johnjaponte theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT alfredogmayor theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT montserenom theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT cintamoraleda theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT davidjroberts theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT evelinschwarzer theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT peternlesouef theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT louisschofield theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT chetanechitnis theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT deniseldoolan theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT pedrolalonso theroleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT caterinaguinovart roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT carlotadobano roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT quiquebassat roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT augustonhabomba roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT llorencquinto roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT marianeliamanaca roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT ruthaguilar roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT mauriciohrodriguez roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT arnoldobarbosa roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT johnjaponte roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT alfredogmayor roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT montserenom roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT cintamoraleda roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT davidjroberts roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT evelinschwarzer roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT peternlesouef roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT louisschofield roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT chetanechitnis roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT deniseldoolan roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
AT pedrolalonso roleofageandexposuretoplasmodiumfalciparumintherateofacquisitionofnaturallyacquiredimmunityarandomizedcontrolledtrial
_version_ 1725964127670632448